APA (7th ed.) Citation

SB, C., P, E., MW, G., M, D., RA, F., MC, G., . . . Group, R. T. (2006). Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis & Rheumatism, 54(9), 2793. https://doi.org/10.1002/art.22025

Chicago Style (17th ed.) Citation

SB, Cohen, et al. "Rituximab for Rheumatoid Arthritis Refractory to Anti-tumor Necrosis Factor Therapy: Results of a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial Evaluating Primary Efficacy and Safety at Twenty-four Weeks." Arthritis & Rheumatism 54, no. 9 (2006): 2793. https://doi.org/10.1002/art.22025.

MLA (9th ed.) Citation

SB, Cohen, et al. "Rituximab for Rheumatoid Arthritis Refractory to Anti-tumor Necrosis Factor Therapy: Results of a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial Evaluating Primary Efficacy and Safety at Twenty-four Weeks." Arthritis & Rheumatism, vol. 54, no. 9, 2006, p. 2793, https://doi.org/10.1002/art.22025.